Stargardt Disease (Fundus Flavimaculatus)

Overview

Genetics

Pathophysiology

Clinical Features

Symptoms

• Gradual central vision loss, typically onset in childhood or adolescence (ages 6–20), occasionally later
• Difficulty reading is a common complaint
• Importantly, early visual decline is often out of proportion to fundoscopic findings — patients, particularly children, may be incorrectly labeled as malingerers
• A quarter of childhood-onset STGD1 cases have no visible retinal lesions at presentation; OCT clarifies the diagnosis

Fundoscopic Signs (progressive)

1. Normal-appearing fundus or non-specific foveal granularity/mottling
2. Yellow-white pisciform (fish-shaped) flecks at the level of the RPE — may be confined to the posterior pole or extend to the mid-periphery
3. "Snail-slime" maculopathy or "beaten-bronze/beaten-metal" paramacular appearance
4. Atrophic macular degeneration — may have a bull's-eye configuration or geographic atrophy
5. Occasionally: macular neovascularization (rare)

Fundus Photo — Characteristic Flecks

Investigations

FAF image — Stargardt disease

Differential Diagnosis

• Fundus albipunctatus — stationary night blindness with discrete white dots; ERG normalizes after dark adaptation
• Retinitis punctata albescens — similar appearance but progressive; abnormal ERG
• Drusen — typically older patients; all lesions hyperfluorescent on FA
• Cone/cone-rod dystrophy — significant color vision deficit; characteristic ERG
• Chloroquine/hydroxychloroquine maculopathy — medication history
• Bull's-eye maculopathy (Batten disease, Spielmeyer-Vogt) — associated dementia/seizures
• Nonphysiologic visual loss — normal ERG, EOG, OCT

Prognosis

Management

Current (Symptomatic)

• Avoid vitamin A supplementation — accelerates lipofuscin accumulation
• UV-blocking sunglasses — protect against light-induced RPE damage
• Low-vision aids and rehabilitation
• Genetic counseling

Emerging Therapies (Clinical Trials)

1. Gene therapy — lentiviral vector delivery of ABCA4 (StarGen trial); recent large-animal studies using dual AAV intein vectors show safety and efficacy (Ferla et al., Sci Adv 2025)
2. Stem cell therapy — RPE cell replacement
3. Pharmacotherapy — reducing lipofuscin/A2E accumulation (e.g., visual cycle modulators)
4. Metformin (oral) — under investigation for neuroprotective effects
5. Base editing — high-efficiency genome editing approaches demonstrated in primate retina (Muller et al., Nat Med 2025)

Associations

• Epilepsy
• Refsum syndrome
• Kearns-Sayre syndrome
• Bassen-Kornzweig syndrome
• Sjögren-Larsson syndrome
• Spinocerebellar and other cerebellar degenerations

⚠️ Recent evidence note (2025): Gene therapy using dual AAV intein vectors for STGD1 has shown safety and efficacy in large animal models (PMID: 40138422), and base editing approaches in primate retina are advancing rapidly (PMID: 39779923). These may update current clinical management guidelines in coming years.

Intraocular Foreign Body (IOFB) — Management

Introduction

• Mechanical injury — cataract formation from capsular injury, vitreous liquefaction, retinal hemorrhages and tears
• Infection — stones and organic matter carry a high risk; endophthalmitis develops in ~1 in 10 cases of penetrating trauma with retained IOFB
• Toxic effects — iron causes siderosis; copper causes chalcosis

Types of Foreign Bodies

⚠️ Even "inert" foreign bodies can be toxic due to coatings or chemical additives. Most BBs and gunshot pellets are 80–90% lead with 10–20% iron.

Clinical Presentation

Symptoms

• Eye pain, decreased vision — or may be completely asymptomatic
• Classic history: hammering metal on metal, power tool use, explosion, shrapnel, high-velocity projectile

Signs

• Visible corneal or scleral perforation site
• Hole in the iris (iris transillumination defect — TID)
• Focal lens opacity or embedded FB in lens
• Vitreous hemorrhage
• Microcystic (epithelial) edema of the peripheral cornea — clue to a hidden AC angle foreign body
• Long-standing iron IOFBs: anisocoria, heterochromia iridis, anterior subcapsular cataract, pigmentary retinopathy, optic atrophy (siderosis)

Clinical image — IOFB in vitreous

Clinical image — IOFB with vitreous hemorrhage

Workup / Diagnosis

History

• Nature and composition of the foreign body
• Time of last meal (for surgical planning)
• Mechanism — hammering, power tools, fireworks, gunshot

Examination

• Visual acuity in all patients
• Slit-lamp — inspect AC, iris (TID), lens (disruption/cataract/embedded FB)
• IOP measurement
• Careful gonioscopy if no wound leak detected and globe appears intact
• Dilated fundus exam with indirect ophthalmoscopy
• Apply topical fluorescein to identify entry wounds

Minimize pressure on the eye at all times.

Imaging

Wood, glass, and plastic may be difficult to visualize on CT — always mention suspicion of nonmetallic IOFB to the radiologist.

Immediate Emergency Management

1. NPO (nothing by mouth) — hospitalize and keep nil by mouth until surgical repair
2. Rigid protective shield over the eye — do NOT patch (patching increases pressure)
3. Do NOT apply pressure to the globe — further examination deferred to the operating room if perforation is obvious
4. Tetanus prophylaxis as indicated
5. Systemic broad-spectrum antibiotics (gram-positive + gram-negative coverage):
   • Vancomycin 1 g IV q12h + Ceftazidime 1 g IV q12h, OR
   • Ciprofloxacin 400 mg IV q12h, OR
   • Moxifloxacin 400 mg IV daily
   • ⚠️ Fluoroquinolones contraindicated in children and pregnant women
6. Cycloplegia (e.g., atropine 1% b.i.d.) for posterior-segment IOFBs
7. Emergent ophthalmology consultation

Surgical Removal

Indications

• All acute IOFBs — urgent removal reduces risk of endophthalmitis and proliferative vitreoretinopathy (PVR)
• Copper or contaminated foreign bodies — especially urgent
• Chronic IOFB — remove if causing severe recurrent inflammation, in the visual axis, or causing siderosis
• Inert, intraorbital FBs (not intraocular) may sometimes be left if removal causes more damage than presence

Surgical Techniques

Antibiotic Prophylaxis for Endophthalmitis

• Oral: Ciprofloxacin 750 mg twice daily or Moxifloxacin 400 mg once daily
• Topical antibiotic + steroid + cycloplegia for open globe
• Prophylactic intravitreal antibiotics — especially in high-risk cases (agricultural injuries, soil/vegetable contamination)
• Culture the removed IOFB

Endophthalmitis risk: ~10% with retained IOFB after penetrating trauma. Pathogens: Staphylococcus spp. and Bacillus spp. account for ~90% of culture-positive cases.

Complications of Retained IOFBs

Siderosis (Iron/Steel)

• Iron dissociates and deposits in RPE, lens epithelium, iris and ciliary body epithelium
• Signs: Anterior capsular cataract with radially distributed iron deposits, heterochromia iridis (reddish-brown iris staining), pigmentary retinopathy → geographic RPE atrophy, trabecular damage → glaucoma
• ERG: Progressive attenuation of the b-wave
• A missed ferrous IOFB → late visual loss from siderosis

Chalcosis (Copper alloy — low copper content)

• Dissociated copper deposits intraocularly — resembles Wilson disease picture
• Signs: Kayser-Fleischer ring, anterior "sunflower" cataract, golden retinal plaques
• Visual function may be preserved (copper is less retinotoxic than iron)
• Pure copper (>85%) → violent endophthalmitis-like reaction → phthisis bulbi

Proliferative Vitreoretinopathy (PVR)

• A major risk of delayed IOFB removal

Follow-Up

• Close inpatient observation for signs of inflammation or infection
• Post-op imaging (CT, B-scan, or UBM) if uncertainty about complete removal
• Serial ERGs if IOFB is left in place — to detect early siderosis (b-wave attenuation)
• Long-term periodic follow-up for years — watch for delayed inflammatory reactions in both eyes (sympathetic ophthalmia risk)

Anesthesia Note (for Emergency Physicians)

📌 Recent review (2024): A review in Frontiers in Ophthalmology on advances in IOFB management is available (PMID: 39285858) for updated surgical and prognostic considerations.